Results: Maximum tolerated doses were 320 mg, 480 mg and 640 mg for continuous (n=47), 4/7 (n=21) and 2/7 (n=22) schedules, respectively. Dose-limiting toxicities were rash and diarrhea for continuous, hyperglycemia for 2/7, and none for 4/7. Common adverse events were diarrhea (78%) and nausea (49%) and, for CTCAE grade ≥3 events, hyperglycemia (20%). The recommended Phase 2 dose (480 mg bid, 4/7 intermittent) was assessed in PIK3CA-mutant breast and gynecologic expansion cohorts: 46% and 56% of patients, respectively, showed a reduction in tumor size, with RECIST responses of 4% and 8%. These responses were less than the pre-specified 20% response rate; therefore, the criteria to stop further recruitment to the PIK3CA cohort were met. 
Introduction
AKT is a serine/threonine protein kinase that functions as a key node in the phosphatidylinositol-3-kinase (PI3K)/AKT network (also known as the PI3K/AKT/mTOR pathway), with a fundamental role in cell survival and proliferation (1) . AKT is overexpressed or activated in a wide range of solid and hematologic malignancies, and aberrant AKT signaling is also associated with resistance to established cancer therapies, as well as advanced disease and/or poor prognosis (2) .
AZD5363 is a potent, selective inhibitor of the kinase activity of all three AKT isoforms (AKT1, -2, and -3) (3). In vitro, AZD5363 inhibited tumor cell proliferation and phosphorylation of the AKT substrates PRAS40 and GSK3 , as well as the downstream pathway protein S6. In vivo, AZD5363 inhibited tumor growth in xenograft models and remained pharmacodynamically active for at least 24 hours (3). Preclinically, sensitivity to AZD5363 has been strongly related to the presence of PIK3CA mutations (4, 5) , a trend that has also been observed with other inhibitors of the PI3K/AKT/mTOR pathway (6) . PIK3CA mutations are found in breast and gynecologic cancers, and evaluation of AZD5363 in these settings is warranted (1) .
We report the first-in-human study of AZD5363, which evaluated safety, pharmacokinetics (PK), and pharmacodynamics (PD) in three schedules and recommended a Phase 2 dose for future development. We also report the first evaluation of an AKT inhibitor used as a single agent in a PIK3CA-mutated breast and ovarian cancer population.
Materials and methods

Study design
This is a multipart, Phase 1, open-label, multicenter study of oral AZD5363 in patients with advanced solid malignancies (Study 1; NCT01226316; Supplementary Figure 1) . Parts A and B were, respectively, the dose-escalation and -expansion phase. Part C focused on an expansion cohort of patients with a PIK3CA tumor mutation. An additional expansion cohort of patients with an AKT1 tumor mutation (Part D) will be reported separately.
Patients
All patients were aged ≥18 years with a WHO performance status of 0-1 and minimum life expectancy of 12 weeks. Patients in Part C had advanced estrogen receptor positive (ER+) or human epidermal growth factor receptor 2 positive (HER2+) breast cancer (based on local testing) (7) or gynecologic (ovarian, cervical, or endometrial) cancer, with any PIK3CA mutation detected by local or central testing, and at least one measurable lesion. Additionally for Part C, where known, other solid tumors (ie not breast or gynecologic) should be negative for mutations of KRAS, NRAS, HRAS, and BRAF. Key exclusion criteria are summarized in the supplementary material.
Study objectives
The primary objective of Parts A and B was to investigate the safety and tolerability of oral AZD5363 and to define a recommended monotherapy dose and schedule for further clinical evaluation. Secondary objectives included PK evaluation of AZD5363 and preliminary assessment of antitumor activity. The objectives of Part C were to investigate safety, tolerability, PK, and antitumor activity of the defined AZD5363 dosing schedule in patients with ER+ or HER2+ breast cancer or gynecologic cancer harboring a PIK3CA mutation. Exploratory objectives of Study 1 overall included the characterization of the PD effects of AZD5363 in paired tumor biopsies and in platelet-rich plasma (PRP; Parts A and B).
Study design and treatment
Part A -dose escalation
Cohorts of 3-6 unselected patients received a single starting dose of 80 mg of AZD5363 and, after a 3-to 7-day washout, AZD5363 twice daily (bid). The dosing cycle was 21 days, excluding the run-in dose. Upon reaching a continuous dose considered appropriate by the Safety Review Committee (SRC), two intermittent dosing schedules were initiated in parallel: 4 days on, 3 days off every week (4/7) and 2 days on, 5 days off every week (2/7). Dose escalation continued for each schedule until a non-tolerated dose was attained (≥2/6 dose-limiting toxicities [DLTs] ) and a maximum tolerated dose (MTD) was identified. Definitions of DLTs are provided in the supplementary material.
Part B -dose expansion
To confirm selection of the recommended dose for the schedules explored in Part A, the safety profile and tolerability were evaluated in up to nine additional unselected patients.
The SRC also reviewed safety and tolerability data on an ongoing basis.
Part C -expansion in PIK3CA-mutant patients
Two cohorts of patients with PIK3CA-mutant ER+ or HER2+ breast cancers (Cb cohort) or gynecologic cancers (Cg cohort) received the recommended dose and schedule identified from Parts A and B. Each cohort permitted a maximum of 120 patients; recruitment to each cohort was prospectively contingent on positive interim efficacy and safety data reviews after 20 and 40 patients had the opportunity to be followed for ≥12 weeks.
The trial (Study 1; NCT01226316) was performed in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics (8) . The local ethics committee or independent review board at each investigator site approved the protocol prior to study commencement. All patients provided written informed consent prior to study participation.
Assessments
Safety and tolerability were assessed by continual monitoring of adverse events (AEs) 
Statistical methods
All patients who received ≥1 dose of AZD5363 were included in the safety analyses.
Safety and tolerability were assessed in terms of AEs, serious AEs, deaths, laboratory data, vital signs, electrocardiogram (ECG) changes, left ventricular ejection fraction, and abnormalities of glucose metabolism. All patients who provided appropriate samples were assessed for PK and PD. Standard non-compartmental PK parameters were calculated using Phoenix WinNonlin ® version 6 software. Modeling and simulation were applied to emerging safety, PK, and PD data to provide an understanding of any dose exposure-response relationships, and to support dose-escalation and dosingschedule decisions. Preclinical PK, PD, and efficacy data were used to define PoM thresholds for the reduction of phosphorylation of GSK3 and PRAS40 to provide confidence that on-target PoM was achieved at tolerable doses (described in the supplementary material).
The pre-defined formal trigger in Part C to stop the study for futility was four or fewer responses by RECIST once 20 patients in each cohort had the opportunity to be followed for 12 weeks, ie a ≤10% chance that the true proportion of RECIST responses was ≥40%. Antitumor activity was assessed by response rate, with two-sided ClopperPearson confidence intervals to provide probability statements of the efficacy signal.
Role of the funding source
This study was sponsored by AstraZeneca. The study funder, AstraZeneca, provided organizational support, obtained data, did the analyses, and had a role in data interpretation and writing of the manuscript. All authors had access to study data. The corresponding author (UB) had unrestricted access to all study data and had final responsibility for the decision to submit for publication.
Results
Dose escalation and expansion (Parts A and B)
Patients
A total of 90 patients were assigned to treatment; 47, 21, and 22 received AZD5363 in the continuous, 4/7, and 2/7 intermittent schedules, respectively. Patient demographic and baseline clinical characteristics are shown in Table 1 . The most common cancers were rectal/colorectal (29%). By the time of the final analysis, all 90 patients had ceased study medication, most commonly for progression of the disease under investigation (64%).
Safety and tolerability
The MTDs of the continuous, 4/7, and 2/7 schedules were 320, 480, and 640 mg bid, respectively (Supplementary Figure 2) . For the continuous dosing schedule, the 600 mg bid cohort was not tolerated: 2/2 patients experienced DLTs (one event of grade 3 rash and one of grade 4 rash). An intermediate dose level of 480 mg bid was, therefore, investigated; in this cohort, 4/6 patients experienced DLTs (three events of grade 3 rash and one of grade 3 diarrhea). At a further lower dose level of 320 mg bid, 0/12 patients experienced DLTs, and this dose was considered the MTD for the continuous schedule.
In the 4/7 intermittent dosing schedule, no DLTs were observed in the 480 mg bid (n=11) and 640 mg bid (n=10) cohorts; however, based on the presence of chronic toxicities such as rash and diarrhea observed outside the first 21-day cycle DLT window, the lower dose of 480 mg bid was considered tolerable and appropriate for chronic use with 4/7 dosing. In the 2/7 intermittent dosing schedule, at 800 mg bid, 3/14 patients had DLTs (two events of grade 4 hyperglycemia and one of grade 3 hyperglycemia); again, considering observed chronic toxicities, a dose of 640 mg bid was explored. In this cohort, DLTs were observed in 1/8 patients (one event of grade 4 hyperglycemia), and the 640 mg bid dose was considered tolerable (Supplementary Figure 2) . All DLTs were reversible; no events of ketoacidosis were reported in patients with hyperglycemia. Two patients remained on AZD5363 for longer than 6 months (one patient on the 480 mg bid 4/7 schedule and one patient on the 800 mg bid 2/7 schedule); the median duration of exposure was 44 days (range 1 507).
The most frequently reported AEs across all dosing schedules were gastrointestinal events (diarrhea, vomiting, nausea) ( Table 2 ). Grade ≥3 AEs were experienced by 56 patients (62%), most commonly hyperglycemia (n=18; 20%), diarrhea (n=13; 14%) and maculopapular rash (n=10; 11%) (Supplementary Table 5 ). Overall, 21 patients (23%) had an AE leading to discontinuation; the most common (≥2%) were diarrhea (8%), maculopapular rash (8%), and dehydration (2%). AEs leading to dose interruption or reduction were experienced by 29 (32%) and 21 (23%) patients, respectively. No AEs resulted in death, and seven patients died as a result of the disease under investigation.
All 90 patients had blood glucose levels above the upper limit of normal at some point following initiation of therapy with AZD5363 -this developed within the first 2 weeks of multiple dosing in the majority of patients (77%). Grade 3 elevations (>13.9 mmol/L) were seen in 33 patients (37%). No other clinically important trends were observed in laboratory parameters, vital signs, physical findings, or ECG changes.
Pharmacokinetics and pharmacodynamics
Plasma concentrations of AZD5363 showed a median t max of 2 hours (range 0. 
Proof of target engagement in tumor tissue
Evaluable paired tumor biopsies from 12 patients (nine from the current study [Study 1; NCT01226316] and three from Study 4 (AstraZeneca study D3610C00004)
[NCT01353781]) (9) who received a range of doses and schedules were evaluated to assess PoM. Over 50% inhibition of pPRAS40 was seen in 4/12 paired biopsies and >30% decrease in pGSK3 was observed in 6/11 paired biopsies; 4/11 samples met both endpoints ( Figure 3A and 3B, Supplementary Table 1) . Downregulation of PD biomarkers was observed >4 hours post-dose, including with intermittent dosing (Supplementary Table 1 ). These data are consistent with the PD response achieved in BT474c xenografts grown in nude mice at a dose that resulted in significant tumor growth inhibition (Supplementary Figure 4) . AZD5363 treatment also increased phosphorylation levels of AKT (consistent with ATP competitive mechanism of action), inhibited phosphorylation of 4EBP1, and resulted in inhibition of Foxo nuclear translocation ( Figure 3A ) (10) . In the five patients treated with the recommended Phase 2 dose and schedule (480 mg bid, 4/7 intermittent), the average percentage decrease from baseline for pPRAS40 (59%) and pGSK3b (67%) exceeded the PD response required for preclinical efficacy ( Figure 3B ).
Recommended Phase 2 dose
Based on preclinical models, the trough plasma concentrations achieved at the tolerable dose of 320 mg bid on a continuous schedule exceeded those required for xenograft activity (Supplementary Figure 4) . Further modeling has suggested that a 1.3-and 1.7-fold dose level over continuous dosing would be efficacious when administered on the 4/7 and 2/7 schedules, respectively (11) . Based on the combination of tolerability profile, PK profile achieved, evidence of target engagement in normal and tumor tissue, and modeling predictions of efficacy, the dose of 480 mg bid on a 4/7 intermittent schedule was declared as the recommended Phase 2 dose. The dose level of 640 mg bid 2/7 was also tolerable, achieved adequate PK exposure, showed evidence of target modulation in PRP (tumor biopsy data were not available in this schedule), and was predicted to be efficacious from modeling of preclinical data. This schedule could be of use in combination studies in the future. Results of PIK3CA mutational analysis in tissue and ctDNA and other exploratory biomarkers (eg PTEN status, ESR1 mutation status) are shown in Figure 4A and Supplementary Table 4 and described in detail in the supplementary material.
The safety profile of AZD5363 in Part C, which is described in detail in the supplementary material, was consistent with the findings in Parts A and B.
Discussion
This first-in-human study assessed the safety and tolerability of AZD5363 and identified a recommended dosing schedule for further clinical evaluation. The study also explored single-agent activity of AZD5363 in populations of patients who had metastatic breast and gynecologic cancers with PIK3CA mutations.
DLTs of AZD5363 in the dose-escalation part of our study (Part A) were skin rash, diarrhea, and hyperglycemia. Whereas skin rash and diarrhea were predominant in the continuous schedule, hyperglycemia associated with the period of C max was predominant in the intermittent 2/7 schedule, where highest AZD5363 exposures were achieved. The cases of skin rash and diarrhea were self-limiting and recovered once treatment stopped. These AEs have been noted in Phase 1 studies of other AKT inhibitors, such as the allosteric inhibitor MK2206 or kinase inhibitors such as GSK2141795 and ipatasertib (GDC-0068) (1, (12) (13) (14) (15) (16) (17) . Hyperglycemia development was acute and indicative of the inhibitory effect of AZD5363 on AKT, a key regulator of glucose transport and metabolism in peripheral tissues and the liver (17) . No patients had ketotic or non-ketotic hyperosmolar coma. However, patients with diabetes were excluded from our study and it is not possible to rule out these complications in a diabetic population. A number of patients with hyperglycemia were treated with metformin according to a protocol-defined algorithm; however, the efficacy of this intervention requires further study.
The trough concentrations predicted to provide efficacy based on preclinical modeling were exceeded in patients receiving intermittent schedules. PD analyses in PRP showed levels of target inhibition that were consistent with PoM in pre-and post-biopsies from 12 patients. Owing to the limited sample size, no formal statistical testing relating to the PD changes in tumor tissue was done. Collectively, the toxicity, PK, and PD data, critical aspects of the pharmacologic audit trail (18) , have been used to select the dose of 480 mg bid intermittent 4/7 for Part C expansion and as the recommended Phase 2 dose and schedule of AZD5363 monotherapy.
Proof-of-principle responses were observed in the dose-escalation phase of our study (eg PIK3CA E545K mutant cervical cancer). Within the PIK3CA expansion cohorts, a number of patients showed regression of their tumors (46% in breast cancer and 56% in gynecologic cancers; Figure 4B ). However, the RECIST response rates in the two expansion cohorts of patients with PIK3CA mutations in ER+ breast cancer and gynecologic cancers were modest (4% and 8%, respectively). Several considerations should be made. PIK3CA mutational status can 'change' upon disease recurrence (supplementary material and Supplementary Figure 3) , reflecting intra-tumoral heterogeneity and clonal selection (19, 20) , and studies on the role of PIK3CA as a predictive biomarker of PI3K pathway inhibitors have not been conclusive (21) . Rewiring of signal transduction pathways and clonal evolution are critical mechanisms of resistance, and combination therapy is almost inevitably necessary (26, 27) . For example, the approved PI3K pathway (mTOR) inhibitor everolimus had modest clinical efficacy when used as a single agent in breast cancer (28) . We consider the tumor shrinkage caused by AZD5363 as a single agent in a significant number of patients in the PIK3CA-mutant cohorts to be an encouraging proof of concept and the basis for evaluation of the drug in combination therapy. Our Phase 1 study has optimized multiple intermittent regimens in order to provide flexibility in the use of such a novel agent in combination with multiple standard-of-care or experimental agents (29) . (29) 7 (8) 6 (7) 5 (6) 5 (6) 4 (4) 4 ( (13) 27 (30) 51 (57) 3.3 (2) 1 (2) 6 (10) 11 (19) 41 (70) 5.0 (3) a Other includes cancers that occurred in one or two patients. NA, not available 
